EDO is focused on the preclinical and clinical development of treatments for cancer types where there are currently limited options for patients.
The company collaborates with a worldwide network of clinical connections and experienced partners to develop differentiated compounds for a range of cancers, including haematological malignancies and advanced solid tumours. Through these partnerships, EDO has been able to streamline the drug development process by procuring relevant expertise and specialist services.
EDO is part of the Mundipharma global network of independent associated companies, which operate in over 120 countries worldwide.
EDO supports the rapid development of ‘smart chemotherapies’ from initial concept right through to the late stages of clinical development.